Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy
H. Al-janabi, K. Moyes, R. J. Allen, M. Fisher, M. Crespo, B. Gurel, P. Rescigno, J. De Bono, H. Nunns, C. Bailey, A. Juncker-Jensen, M. Muthana, W. A. Phillips, H. Pearson, M.-E. Taplin, , C. E. Lewis
This study shows targeting a STING agonist to perivascular macrophages in ADT-treated prostate tumors delays castration resistance prostate cancer onset.
bioRxiv · Apr 11, 2024Cancer Biology